STUDY OBJECTIVE: To estimate the prevalence of congenital anomalies between the offspring of women exposed and unexposed to asthma drugs during early pregnancy. DESIGN: Matched cohort study. DATABASE: The United Kingdom's General Practice Research Database. PATIENTS: Women exposed to asthma drugs during early pregnancy and a sample of matched unexposed pregnant women. MEASUREMENTS AND MAIN RESULTS: The prevalence of any anomaly among unexposed and exposed women was 27.8 (95% confidence interval [CI] 25.4-30.6)/1000 pregnancies and 31.3 (95% CI 27.7-35.5)/1000 pregnancies, respectively (relative risk [RR] 1.1 95% CI 1.0-1.3). CONCLUSION: Our findings suggest that asthma drugs, overall, do not increase the risk of congenital anomalies in the offspring when taken during the first trimester of pregnancy.
STUDY OBJECTIVE: To estimate the prevalence of congenital anomalies between the offspring of women exposed and unexposed to asthma drugs during early pregnancy. DESIGN: Matched cohort study. DATABASE: The United Kingdom's General Practice Research Database. PATIENTS: Women exposed to asthma drugs during early pregnancy and a sample of matched unexposed pregnant women. MEASUREMENTS AND MAIN RESULTS: The prevalence of any anomaly among unexposed and exposed women was 27.8 (95% confidence interval [CI] 25.4-30.6)/1000 pregnancies and 31.3 (95% CI 27.7-35.5)/1000 pregnancies, respectively (relative risk [RR] 1.1 95% CI 1.0-1.3). CONCLUSION: Our findings suggest that asthma drugs, overall, do not increase the risk of congenital anomalies in the offspring when taken during the first trimester of pregnancy.
Authors: Meredith M Howley; Eleni A Papadopoulos; Carla M Van Bennekom; Alissa R Van Zutphen; Suzan L Carmichael; JeanPierre W Munsie; Michele L Herdt; Marilyn L Browne Journal: J Allergy Clin Immunol Pract Date: 2020-07-31